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Abstract: The development of high-titer inhibitors to FVIII and less often to other coagulation 
factors are the most serious complication of hemophilia therapy and makes treatment of 
bleeds very challenging. At present, bypassing agents, such as factor eight inhibitor bypass 
activity (FEIBA) and activated recombinant factor VII (rFVIIa) are the only coagulation factor 
concentrates available for the treatment of bleeds in inhibitor patients. Both products are effective 
and safe, and their efﬁ  cacy has been found to be comparable (approximately 80%) in a recent 
prospective study. A signiﬁ  cant number of patients report a better effect of one or the other of 
the products, and in a minority of the patients none of the products are particularly effective. 
The hemostatic efﬁ  cacy of bypassing agents is not considered equal to that of coagulation factor 
replacement in patients without inhibitors by most physicians. An improvement in hemostatic 
efﬁ  cacy may be achieved by optimizing the dosing of by passing agents. However, the lack of 
standardized and validated laboratory assays reﬂ  ecting the hemostatic efﬁ  cacy of the bypassing 
agents is an obstacle to this achievement.
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Introduction
The risk of blood-borne pathogens in coagulation factor concentrates has been virtually 
eliminated by the introduction of effective virus inactivation procedures for plasma-
derived concentrates and the development of recombinant factor concentrates. At 
present, the development of inhibitors is the most serious complication to the use of 
these concentrates in hemophilia care, and patients with inhibitors represent a major 
therapeutic challenge. Inhibitors develop in 20–30% of patients with severe hemophilia 
A [factor (F) VIII levels <1%] and in 5% or less of patients with severe hemophilia B 
(FIX levels <1%) (Scharrer et al 1999; Wight and Paisly 2003; UK Haemophilia Center 
Doctors’ Organization (UKHCDO) 2004). Inhibitors may occasionally also develop 
in patients with mild or moderate hemophilia. Inhibitors are inhibiting or neutralizing 
alloantibodies to FVIII/FIX which usually develop after 10–20 exposures to FVIII/FIX 
concentrates. Inhibitors may be transient or resolve with immune tolerance therapy 
(ITI), but in 10–15% of hemophilia A patients inhibitors remain clinically signiﬁ  cant 
(high-titer). ITI is far less successful in managing FIX inhibitors than FVIII inhibitors 
(Key 2004).
Inhibitors to FVIII/FIX preclude the use of standard and effective factor concen-
trates. Although bleeds do not occur more frequently than in non-inhibitor patients, the 
bleeds may be much more difﬁ  cult to control, and the presence of inhibitors increases 
the risk of uncontrollable bleeding, disability and premature death (Triemstra et al 1995; 
UK Haemophilia Center Doctors’ Organization [UKHCDO] 2004). Progressive and
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disabling joint disease is more prevalent in inhibitor patients 
than in non-inhibitor patients (Leissinger et al 2001).
Acquired hemophilia is a rare condition characterized 
by the development of neutralizing or inactivating autoan-
tibodies to FVIII in patients with previously normal FVIII 
levels. An incidence of 0.2–1 patient per million persons per 
year has been reported (Shapiro and Hultin 1975; Lottenberg 
et al 1987; Holme et al 2005). The disease usually develops 
late in life, and it is associated with high morbidity (life-
threatening bleeds in more than 85% of patients) and high 
mortality varying from 8% to 22% (Green and Lechner 
1981; Hay et al 1997; Delgado et al 2003). Although the 
clinical phenotype of acquired hemophilia differs from that 
of congenital hemophilia, managing bleeds poses more or 
less the same challenges to the clinician.
Inhibitors are measured with the Bethesda assay or its 
modiﬁ  cations, and titers are expressed in Bethesda units 
(BU).
The development of inhibitors is the most pressing 
concern in hemophilia care to day, and there is great interest 
in methods to reduce the risk of inhibitor development, 
improve on immune tolerance therapy regimens, treat bleeds, 
provide hemostasis during surgery and develop effective 
laboratory methods to assess bypassing therapy. In this 
review we will focus on the management of bleeds and the 
prevention of chronic joint disease.
Treatment of bleeds
Apart from the severity and location of the bleed, the 
characteristics of the inhibitor are the most important factors 
to consider in the management of a bleeding episode in a 
particular patient. Treatment options are dependent on the 
inhibitor titer as well as whether the inhibitor is low or high 
responding. Knowledge of the patient’s previous response 
to speciﬁ  c therapies also provides important information 
selecting the best hemostatic therapy. Approximately 
70% of the inhibitors in hemophilia A patients are due to 
high-responding antibodies which show a substantial rise 
in titer (5 BU or higher) within 4–6 days of exposure to 
FVIII (anamnestic response). In hemophilia B more than 
80% are of the high responder type. Low-responding 
inhibitors (generally <5 BU) are not anamnestic, and they 
are much more likely to be transient. A bleed in a low-titer, 
low-responder patient can usually be treated by standard fac-
tor concentrates, but much higher doses than in non-inhibitor 
patients have to be used to overcome the inhibitor. In general, 
standard factor concentrates, even in higher doses, are not 
effective in patients with high-titer inhibitors. Hemostatic 
agents with proven efﬁ  cacy in the treatment of bleeds in 
inhibitor patients are presented in Table 1. However, only 
bypassing agents are currently available. Prothombin 
complex concentrates (PCCs) and activated prothrombin 
complex concentrates (aPCCs), plasma-derived products 
containing FII, FVII, FIX, FX and small amounts of FVIII, 
have been available for the treatment of inhibitor patients 
for more than 30 years. aPCCs, in contrast to PCCs, contain 
activated FVII and small amounts of activated FII, FIX and 
FX. PCCs have been shown to be less effective than aPCCs 
and to show a higher rate of adverse reaction (Sjamsoedin 
et al 1981; Lusher et al 1983; Negrier et al 1997). Currently, 
PCCs are seldom used to treat inhibitor patients. In the 
1990s, recombinant activated FVII (rFVIIa) concentrate were 
introduced for treatment of inhibitor patients. In clinical trials 
both aPCCs (factor right inhibitor bypass activity, [FEIBA]; 
Baxter AG, Vienna, Austria) and rFVIIa (NovoSeven, 
Novo Nordisk AS, Bagsværd, Denmark) have shown 
excellent efﬁ  cacy (80–90%) in the management of bleeding 
in inhibitor patients (Hilgartner et al 1990; Key et al 1998). 
The hemostatic actions of these agents are different and 
still not fully unraveled. Nevertheless, both products appear 
effective, safe and well tolerated, but clinical evidence from 
randomized, prospective trials comparing the two agents 
as a guide to their optimal use in inhibitor patients are still 
lacking. There are ongoing studies addressing this issue, but 
the ﬁ  nal reports are still pending.
The FENOC (The FEIBA versus NovoSeven Comparative 
Study) study compared the hemostatic effect of FEIBA on 
joint hemorrhages with that of rFVIIa. The main objective 
was to compare the efﬁ  cacy of a single dose of FEIBA (target 
dose, 85 IU/kg bw) with two doses of rFVIIa (target dose, 
105 µg/kg bw), and enrollment was stopped in December 
2004. Preliminary results show that the treatment was 
effective in 80.9% and 78.7% of the patients with FEIBA 
and rFVIIa, respectively (Astermark et al 2007). The study 
also show that a signiﬁ  cant number of patients report a better 
effect of one or the other of the products. A second study 
is addressing whether a single high dose (270 µg/kg) of 
rFVIIa is more effective than the currently approved dosing 
(90 µg/kg for 3 doses). Data from uncontrolled trials suggest 
that higher doses of rFVIIa are more effective than standard 
dose (Kenet et al 2003; Seremetis 2003). The results from 
the prospective, randomized study are pending.
Some patients do not respond well to either FEIBA or 
rFVIIa. The combined use of FEIBA and rFVIIa has been put 
forward as an approach for bleeds that are refractory to either 
agent alone (Key et al 2002). A recent case report on the use Vascular Health and Risk Management 2007:3(4) 529
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of sequential therapy with FEIBA and rFVIIa demonstrated 
the efﬁ  cacy and safety of this approach (Schneiderman et al 
2004). However, the issue of concomitant use of FEIBA and 
rFVIIa is a matter of dispute among hematologists (Allen 
and Aledort 2006).
Several clinical features distinguish FIX inhibitors 
from FVIII inhibitors. With respect to treatment of bleeds, 
anaphylaxis or anaphylactoid reactions to FIX-containing 
concentrates are, although rare, the most important feature 
in terms of morbidity. A history of anaphylaxis to FIX-
containing concentrates was recently shown in a majority of 
hemophilia B patients with high-titer inhibitors, and rFVIIa 
seems to be a suitable treatment of choice in these patients 
(Warrier 2003; Key 2004).
Prophylaxis
In non-inhibitor patients prophylactic treatment with coagu-
lation factor concentrates prevents bleeding and resultant 
joint damage (Nilsson et al 1992; Funck et al 1998; Kreuz 
et al 1998). Currently, prophylaxis from early childhood to 
prevent end-stage joint disease is recommended in most west-
ern countries. Inhibitor patients have an even greater proba-
bility of developing disabling joint disease than non-inhibitor 
patients (Leissinger et al 2001). Accordingly, the possibility 
of prophylaxis with bypassing agents in inhibitor patients is 
a matter of concern for the hemophilia community. Several 
small studies suggest that daily or every-other-day doses of 
FEIBA of less than 100 IU/kg/day are safe (Leissinger 1999; 
Kreuz et al 2000a, 2000b; Ehrlich et al 2002; Valentino and 
Salit 2002; Hilgartner et al 2003; Ehrlich et al 2002). The 
studies show a reduction in the number of annual bleeds, 
but the results regarding the prevention of progressive joint 
damage are equivocal (Hilgartner et al 2003). There are two 
reports describing prophylaxis with rFVIIa in three patients 
resulting in reduction in severe bleeds and reduced hospi-
talizations (Saxon et al 2001; Young et al 2005). At present, 
a recommendation of prophylaxis with bypassing agents in 
inhibitor patients is not supported by solid clinical evidence. 
There is an on-going study evaluating the efﬁ  cacy of FEIBA 
for prophylaxis in inhibitor patients (PRO-FEIBA study). The 
primary objective of the trial, which has a cross-over design, 
is >50% reduction in the number of bleeds during a 6-month 
period with prophylaxis compared to on-demand therapy.
Monitoring therapeutic efﬁ  cacy
There is no generally accepted laboratory assay to moni-
tor efﬁ  cacy or determine an optimal dose of the bypassing 
agents (Leissinger 2004; Mathew 2006). However, both 
thromboelastography (TEG) and thrombin generation as-
say (TGA) may provide some guidance in the treatment 
of the individual patient. Using these assays it is clearly 
demonstrated that the ex vivo responses to both bypassing 
agents are dose-dependent (Ingerslev et al 2003; Turecek 
et al 2003; Sørensen et al 2004). It is well appreciated 
Table 1 Coagulation factor concentrates with proven efﬁ  cacy in hemophilia patients with high-titer inhibitors
Factor concentrate  Advantage  Disadvantage  Comments
Porcine (p) FVIII  Measurable FVIII levels  Inhibitors often show cross-reactivity with   Plasma derived pFVIII are
    pFVIII or the patients develop pFVIII after   presently not available
    5–10 days of treatment  A recombinant pFVIII concentrate 
    Risk of transmission of porcine viruses  is in clinical development
PPCs  Bypass the need for FVIII  Inferior efﬁ  cacy compared to aPCCs  aPCCs have supplanted the use of 
  Relatively inexpensive  Potentially thrombogenic  PCCs 
    High frequency of infusion related adverse  
   events 
aPCCs  Long history of use  Unpredictable hemostatic response  The risk of thrombotic 
 Efﬁ  cacy of 80–90% in clinical trials  Potentially thrombogenic  complications with standard doses 
  Long-half life compared to rFVIIa  Trace amounts of FVIII leading to anamnesis   is low
  More effective than PCCs  of the inhibitor  Increase in inhibitor titer does not 
  Cost advantage over rFVIIa  Possibility of transmission of human viruses  hamper efﬁ  cacy
    No established laboratory assay to monitor  
   efﬁ  cacy and optimal dosing 
rFVIIa Efﬁ  cacy in 80–90% in clinical trials  Unpredictable hemostatic response  The risk of thrombotic 
  No anamnestic response  Potentially thrombogeneic  complications is low
  No risk of  transmission of human   No established laboratory assay to monitor   Whether the risk of thrombotic 
 viruses  efﬁ  cacy and optimal dosing  complications differ signiﬁ  cantly 
    Short half-life making rFVIIa less convenient   between aPCCs and rFVIIa is an 
    than aPCCs  unresolved issueVascular Health and Risk Management 2007:3(4) 530
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that there is a considerable variation in clinical phenotype 
among patients with severe hemophilia, and this is reﬂ  ected 
by a variation in the results of in vitro testing of hemostatic 
intervention (Ingerslev et al 2003). A good in vitro response 
to rFVIIa usually predicts a similar response to FEIBA, but 
discrepancies are observed in some patients (Ingerslev et al 
2003; Sørensen et al 2004). One of our inhibitor patients 
failed post-surgical prophylaxis with FEIBA following a 
total knee arthroplasty. He was successfully rescued by 
rFVIIa. Ahead of a scheduled arthroplasty of the other knee, 
we have performed in vitro testing of the hemostatic efﬁ  cacy 
of FEIBA and rFVIIa by TEG in collaboration with Sørensen 
and Ingerslev (Center for Haemophilia and Thrombosis, 
Department of Clinical Biochemistry, Aarhus University 
Hospital, Aarhus, Denmark). rFVIIa corresponding to a 100 
µg/kg dose normalized the patient’s clotting proﬁ  le. FEIBA 
corresponding to a 100 IU/kg dose did not normalize the 
patient’s clotting profile, but the clotting profile was 
normalized by increasing FEIBA corresponding to a 200 
IU/kg dose. In the post-surgical prophylaxis setting this 
would result in a daily dose of FEIBA high above the 
maximum recommended dose (200 IU/kg/day). Dargaud 
et al have recently used the TGA to tailor the hemostatic 
treatment during major surgery in an inhibitor patient in 
whom rFVIIa was ineffective treating muscle and joint bleeds 
(Dargaud et al 2005).
FEIBA: mode of action
Testing plasmas deﬁ  cient in different coagulation factors 
using TGA, Turecek et al showed that FEIBA improves 
thrombin generation in all plasmas, except FV-deﬁ  cient 
plasma (Turecek et al 1999, 2003). Similar results were 
accomplished by a complex consisting of activated FX and 
prothrombin indicating that FXa and prothrombin are the 
constituents of FEIBA providing the hemostatic efﬁ  cacy 
(Turecek et al 1999, 2003).
Adverse effects
FEIBA is usually well tolerated. Infusion-related adverse 
events like fever, hives and bronchial spasms are rare 
(<0,04%) (Dimichele and Negrier 2006). FEIBA contains 
trace amounts of FVIII which may produce an anamnestic 
response. The ﬁ  rst report on this phenomenon appeared in 
1977 (Preston et al 1977). Kasper reported a rise in inhibitor 
level to at least twice the pretreatment value in 21% of 
patients following the ﬁ  rst exposure of prothrombin complex 
concentrates, and the proportion of patients who mounted an 
anamnestic response decreased with the number of exposures 
(Kasper 1979). An anamnestic response to FVIII does not 
seem to inﬂ  uence the efﬁ  cacy of FEIBA, and Hilgartner 
et al reported more recently that the inhibitor titre decreased 
during long-term FEIBA prophylaxis (Hilgartner et al 2003). 
FEIBA is a vapour-heated plasma-derived coagulation factor 
concentrate and a potential for viral transmission exists. 
Today, no conﬁ  rmed reports of human immunodeﬁ  ciency 
virus, hepatitis A, hepatitis B or hepatitis C transmission 
have been published.
FEIBA as well as rFVIIa have been associated with 
thromboembolic complications and disseminated intravas-
cular coagulation (DIC). The most serious complications are 
myocardial infarction and cerebral infarction. These are rare 
events associated with large and repeated doses that in most 
cases exceeded the recommended doses (Ehrlich et al 2002). 
There is an on-going dispute whether the risk of thrombo-
embolic complications differs between FEIBA and rFVIIa 
(Aledort 2004; Makris and Veen 2005; Sallah et al 2005).
Conclusion
The development of high-titer inhibitors to FVIII and less 
often to other coagulation factors makes treatment of patients 
with severe bleeding disorders difﬁ  cult. Although bypassing 
agents, such as FEIBA and rFVIIa, are effective and safe in 
controlling bleeding in inhibitor patients, their efﬁ  cacy is not 
considered equal to that of coagulation factor replacement 
in patients without inhibitors. Improvements of hemostatic 
therapies for inhibitor patients are warranted. Patients with 
high-titer inhibitors are prone to serious bleeding episodes and 
development of debilitating joint disease, and many physicians 
still are reluctant to perform surgery in these patients.
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